Category: catalyst-ligand

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.14162-94-8,4-Chloro-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

General procedure: For compound 1, a 1.0 mL aqueous solution of Ni(ClO4)2¡¤6H2O (0.005mmol) was placed at the bottom of a tube, a mixture of methanol and water (1:2, v/v, 3 mL)was gently layered on the top of the solution, and then a 1.0 mL methanol solutionof Bu4N[Fe(Tp*)(CN)3] (0.005 mmol) and 4-chlorine-2,2?-dibipyridine (0.01 mmol)was carefully added as the top layer. After few weeks, red block crystals were obtained,washed with water and air dried.

14162-94-8, The synthetic route of 14162-94-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Jiao, Yu-Shu; Jiao, Cheng-Qi; Meng, Yin-Shan; Liu, Xue-Ru; Zhao, Liang; Liu, Tao; Inorganic Chemistry Communications; vol. 93; (2018); p. 87 – 91;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5,62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

D-Prolinamide (42.8 mg, 375 muiotaetaomicron) and N,N-diisopropylethylamine (65 mu, 380 mumol) were added to a solution of 2-[3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5- dihydro-lH-l,2,4-triazol-l-yl}methyl)-lH-l,2,4-triazol-l-yl]benzoyl chloride (Example 58A, 79.1 mg, 150 muiotaetaomicron) in tetrahydrofuran (2.3 ml). This reaction mixture was stirred for 1 h at room temperature. The crude product was purified by preparative HPLC (Method 4). Lyophihsation of the product containing fractions afforded 53.9 mg (57 % of th.) of the title compound. LC-MS (Method 2): Rt = 1.53 min; MS (ESIpos): m/z = 605 [M+H]+ -NMR (400 MHz, DMSO-d6) delta [ppm]: -0.215 (1.05), -0.008 (3.93), 0.008 (3.02), 0.716 (3.19), 1.701 (2.80), 1.716 (2.72), 1.742 (2.33), 1.759 (3.07), 1.776 (3.57), 1.787 (3.15), 1.798 (2.94), 1.812 (1.93), 2.053 (1.59), 2.073 (1.94), 2.709 (0.57), 3.205 (1.74), 3.231 (1.37), 3.247 (2.09), 3.287 (4.72), 3.373 (0.82), 3.441 (1.05), 3.816 (1.83), 3.824 (1.18), 3.840 (2.10), 3.852 (2.94), 3.860 (1.87), 3.877 (2.98), 3.884 (2.00), 3.974 (4.06), 3.982 (4.47), 4.010 (2.84), 4.019 (2.68), 4.217 (1.80), 4.229 (1.82), 4.309 (2.20), 5.021 (1.30), 5.061 (14.55), 5.069 (10.76), 5.109 (1.19), 6.913 (3.15), 6.928 (5.00), 6.958 (4.94), 6.973 (4.86), 7.064 (3.77), 7.297 (2.31), 7.342 (3.89), 7.411 (1.12), 7.472 (1.37), 7.492 (2.44), 7.509 (1.27), 7.539 (1.39), 7.556 (3.82), 7.577 (3.93), 7.601 (12.46), 7.614 (6.91), 7.617 (8.60), 7.622 (16.00), 7.629 (8.66), 7.635 (11.09), 7.648 (3.33), 7.676 (3.24), 7.696 (2.26), 7.723 (5.02), 7.745 (10.67), 7.752 (12.89), 7.767 (6.68), 7.773 (9.27), 8.933 (10.76).

As the paragraph descriping shows that 62937-45-5 is playing an increasingly important role.

Reference£º
Patent; BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGESELLSCHAFT; COLLIN-KROePELIN, Marie-Pierre; KOLKHOF, Peter; NEUBAUER, Thomas; FUeRSTNER, Chantal; POOK, Elisabeth; WITTWER, Matthias, Beat; LUSTIG, Klemens; TINEL, Hanna; LINDNER, Niels; SCHIRMER, Heiko; (449 pag.)WO2019/81307; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

103946-54-9, 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

87 mg of 4′-methyl- (2,2′-bipyridine) -4-carboxylic acid was dissolved in anhydrous THF and dissolved in anhydrous DMF. Under ice bath conditions, HOBt 55mg and DCC 100mg were completely dissolved and activated for 30min.The prepared HCl ¡¤ Arg (Tos) -Gly-Asp (OBzl) -Ser-OBzl 312 mg was added and the pH adjusted to 8.0-9.0 with DMM. The reaction was stirred at room temperature for 14h,The reaction was monitored by TLC plate. 328 mg (89% of product) of a pink solid powder was obtained., 103946-54-9

The synthetic route of 103946-54-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Capital University of Medical Sciences; Cui Chunying; Lin Na; (23 pag.)CN107320736; (2017); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

128143-89-5, 4′-Chloro-2,2′:6′,2”-terpyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The syntheses of ligands were carried out by literature procedures [48-50]. To a suspensionof KOH in dry DMSO at 50 C, ethylene glycol and its respective polymer (n = 2, 3, or 4)in excess were added. After stirring for 30 min, 4?-chloro-2,2? : 6?,2??-terpyridine was addedand the reaction mixture was stirred for 20 h at this temperature. Upon cooling to roomtemperature, the reacting mixture was treated with deionised water and filtered. The crudeproduct was extracted from the filtrate in dichloromethane (3 ¡Á 30 mL), dried overanhydrous magnesium sulfate, and then the solvent was removed., 128143-89-5

As the paragraph descriping shows that 128143-89-5 is playing an increasingly important role.

Reference£º
Article; Shaira; Jaganyi; Journal of Coordination Chemistry; vol. 67; 17; (2014); p. 2843 – 2857;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4568-71-2,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4568-71-2,3-Benzyl-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride,as a common compound, the synthetic route is as follows.

1-(3-Methoxy-4-hydroxyethoxy-5-iodophenyl)-4-(3,4,5-trimethoxyphenyl)-1,4-butanedione (compound 105) 3,4,5-Trimethoxyphenylvinylketone (4.8 g, 21.6 mmol), 3-methoxy-4-hydroxyethoxy-5-iodobenzaldehyde (5.7 g. 17.8 mmol), and 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride (1.9 g, 7.0 mmol) were stirred in triethylamine (20 mL) at 60¡ã C. for 16 hours. The reaction mixture was then acidified with 10percent HCl, and extracted with dichloromethane. The organic layer was dried over MgSO4, filtered and evaporated in vacuo. The product was purified in column chromatography (silica, 1:1 hexane/ethyl acetate) as a solid (9.7 g, 51percent). 1 H NMR (CDCl3) delta3.41 (m, 4H); 3.90 (m, 2H); 3.92 (s, 3H); 3.93 (s, 9H); 4.26 (t, 2H); 7.29 (s, 2H); 7.57 (d, 1H); 8.08 (d, 1H).

4568-71-2 3-Benzyl-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride 2833352, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Cytomed, Inc.; US5463083; (1995); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

54258-41-2,54258-41-2, 1,10-Phenanthrolin-5-amine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Both compounds were synthesized in the same way. A mixture ofthe appropriate aldehyde [thiophene-2,5-dicarbaldehyde (283 mg,2.02 mmol), furan-2,5-dicarbaldehyde (316 mg, 2.55 mmol)] and5-amino-1,10-phenanthroline [(1091 mg, 5.59 mmol) withthiophene-2,5-dicarbaldehyde, (1458 mg, 7.48 mmol) with furan-2,5-dicarbaldehyde] was refluxed in EtOH (50 mL) containing acatalytic amount of acetic acid for 12 h, giving a suspension. Thereaction mixture was filtered hot, and the solid was washed withEtOH to afford the desired product as a yellow solid.

As the paragraph descriping shows that 54258-41-2 is playing an increasingly important role.

Reference£º
Article; Cheng, Feixiang; He, Chixian; Yu, Shiwen; Yin, Hongju; Inorganica Chimica Acta; vol. 462; (2017); p. 43 – 49;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

66127-01-3,66127-01-3, 3-Bromo-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Compound 1: A mixture of 2-Br-phen (0.80 g, 3.10 mmol), 2-thiophenylboronic acid (0.42 g, 3.28 mmol), Pd(PPh3)4 (0.12 g, 0.10 mmol) and Cs2CO3 (3.03 g, 9.30 mmol) was dissolved in a mixture of dioxane (40 mL) and H2O (8 mL), placed into a degassed three-necked flask and refluxed under an argon atmosphere for 8 h. After the solution was cooled to room temperature, the solvent was removed under reduced pressure and the residue was dissolved in CHCl3 (50 mL), washed with excess water, and dried with anhydrous Na2SO4. The desired compound 1 was finally separated as light yellow solid by silica gel column chromatography using CHCl3/petroleum ether (v:v 5:1) as the eluent in a yield of 0.71 g (87%). Similarly, compounds 3 and L1 were obtained via the same synthetic method in the yields of 42 and 77%, respectively. Compound 3: 1H NMR (300 MHz, CDCl3) delta: 9.45 (d, 1H, J=2.3 Hz, phen), 9.20 (dd, 1H, J=4.4, 1.7 Hz, phen), 8.35 (d, 1H, J=2.3 Hz, phen), 8.25 (dd, 1H, J=8.1, 1.7 Hz, phen), 7.79 (s, 2H, phen), 7.64-7.57 (m, 2H, phenthienyl), 7.45 (dd, 1H, J=5.1, 1.1 Hz, thienyl), 7.20-7.18 (m, 1H, thienyl).

The synthetic route of 66127-01-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Peng, Yu-Xin; Xu, Dan; Wang, Na; Tao, Tao; Hu, Bin; Huang, Wei; Tetrahedron; vol. 72; 24; (2016); p. 3443 – 3453;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4730-54-5,1,4,7-Triazacyclononane,as a common compound, the synthetic route is as follows.

General procedure: To a solution of 1,4,7-triazacyclononane (2 mmol) in distilled ethanol (50 mL) containing molecular sieve was added 1 equiv of aldehyde. The reaction mixture was stirred at room temperature. The solution was filtered and the filtrate was evaporated under reduced pressure to yield the aminal adduct., 4730-54-5

As the paragraph descriping shows that 4730-54-5 is playing an increasingly important role.

Reference£º
Article; Roger, Melissa; Patinec, Veronique; Bourgeois, Martine; Tripier, Raphael; Triki, Smail; Handel, Henri; Tetrahedron; vol. 68; 27-28; (2012); p. 5637 – 5643;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

10534-59-5, Tetrabutylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a stirred solution of a tetrabutylammonium salt of (2S,5R)-N-{[1-tert-butoxycarbonyl (2R, 4S)-4-(morpholin-4-yl)pyrrolidin-2-ylj methoxy } -6-hydroxy-7-oxo- 1,6- diazabicyclo[3.2.ljoctane-2-carboxamide (1.5 g, 0.0032 mol) in dimethylformamide (15 ml) was added sulfur trioxide: dimethylformamide complex (1.0 g, 0.0064 mol) under stirring at temperature of about 0 C. The reaction mixture was stirred at 0 C for 10 minutes and then allowed to warm to 25C. After 1 hr of stirring a solution of tetra butyl ammonium acetate (2.89 g, 0.0096 mol) in water (8 ml) was added to the reaction mixture under continuous stirring. After completion of 1 hr stirring the solvent from the reaction mixture was evaporated under reduced pressure to obtain an oily residue. The residue obtained was then purified by silica gel(60-120 mesh size) column chromatography using 6% Methanol: DCM mixture as an eluant to get required compound. The solvent of the combined fractions were evaporated to provide 1.2 g of the titled compound as white solid, 47% yield. Analysis:Mass: 548.4 (M-1) as free acid; for Molecular weight: 791.07 and Molecular formula:C37H70N60 ftS?H NMR (CDC13, 400 MHz): 5 10.42 (brs, 1H), 4.38-4.28 (m, 1H), 3.98-3.92 (m, 1H), 3.86- 3.68 (m, 5H), 3.62-3.52 (m, 1H), 3.42-3.20 (m, 1OH), 2.98-2.84 (m, 2H), 2.58-2.32 (m, 5H), 2.24-2.14 (m, 1H), 1.96-1.84 (m, 2H), 1.84-1.62 (m, 12H), 1.56-1.42 (m, 17H), 1.06-0.97 (m, 12H).

10534-59-5, 10534-59-5 Tetrabutylammonium acetate 82707, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; WOCKHARDT LIMITED; PATIL, Vijaykumar Jagdishwar; SHENGULE, Sudhir; PAWAR, Mangesh; BHUNIYA, Rajib; MUNSHI, Zaki Ahmed Burhanuddin; JOSHI, Prashant Ratnakar; TAKALKAR, Swapna Shripad; PATEL, Mahesh Vithalbhai; (64 pag.)WO2017/98425; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1662-01-7, 4,7-Diphenyl-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(Cmpd 12): 4,7-Diphenyl-2-(3-pyridyl)-1,10-phenanthroline. n-Butyllithium (18.8 ml of a 1.6 M solution in hexane, 0.03 mol) is added under argon to a cold (-78C) tetrahydrofurane (100 ml). 3-bromopyridine (4.75 g, 0.03 mol) is then added during 15 minutes while keeping the temperature at -78C. The brown solution is stirred 50 minutes at -78C, thereafter finely powdered 4,7-diphenyl-1,10-phenanthroline (6.64g, 0.02 mol) is added and the mixture is allowed to warm to room temperature during 40 minutes. Methanol (30 ml) is then added and the brown solution is evaporated on a rotary evaporator. The residue is dissolved in dichloromethane (300 ml) and methanol (10 ml), manganese dioxide (30 g) is added and the mixture is stirred at room temperature 12 h. The solids are removed by filtration, the filtrate is evaporated and the residue is crystallized from dichloromethane-ethanol and then o-dichlorobenzene to afford 2.1 g of the title compound. Light yellow, microcrystalline powder, mp (DSC in air, scan rate 10Cmin-1) = 268.3-273.5C. 1H-NMR (300 MHz, CD3Cl): 9.46 (d, J=1.8 Hz, 1H), 9.31 (d, J=4.5 Hz, 1H), 8.86 (d, J=11.7 Hz, 1H), 8.73 (d, J=6.6 Hz, 1H), 8.08 (s, 1H), 7.89 (s, 2H), 7.64-7.48 (m, 12H). MS for C29H19N3 (409.49) found M=409.69.

1662-01-7, 1662-01-7 4,7-Diphenyl-1,10-phenanthroline 72812, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BASF SE; EP2161272; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI